Gepon & ezrin-derived peptidesГепон
A synthetic 14-amino-acid peptide based on the human protein ezrin, studied in infection and inflammation research.
What the studies found
Comparison in people · 2004
Gepon and Immunomax in 126 people with acute surgical wound infections
- Complete wound healing by secondary intention
- 18.4 ± 1.3 vs 20.5 ± 1.4 daysp<0.05 as reported
- Clearance of purulent necrotic material
- 9.9 ± 1.2 vs 12.5 ± 1.5 days
- Day-three wound area as percentage of baseline
- 93.5 ± 2.4% vs 96.5 ± 2.1%The paper reports significance against baseline.
In wounds healing by secondary intention, healing averaged 18.4 vs 20.5 days with the combination and comparison care, respectively.
Study notes · methods, sources and limitations
Participants or model 126 surgical patients with acute purulent soft-tissue infection. Combination group: 65. Standard-care comparison: 61.
Design Single-center comparative series. Both groups received surgery and wound care. Outcomes included wound planimetry and time to clearing and healing.
Important limitations
- Concurrent treatments differed. The effect of Gepon alone cannot be estimated from this comparison. The healing figure concerns the secondary-intention subset. The two journals report the same 126 patients and regimen.
Russian Medical Journal. 2004;(24). Also published in Pharmateca. · Publication record
Comparison in people · 2005
Gepon versus valacyclovir in recurrent genital herpes
- Epithelialization and lesion healing
- Reported faster with GeponNumerical effect unavailable in the abstract.
- Length of remission
- No extension with GeponThe abstract describes an extension with valacyclovir.
The authors reported faster lesion healing and less severe recurrence symptoms with Gepon. They reported no extension of remission with Gepon.
Study notes · methods, sources and limitations
Participants or model 42 women with severe recurrent genital herpes. Arm sizes were not stated in the accessible original abstract.
Design Clinical treatment comparison during recurrence, based on the original publisher abstract.
Important limitations
- The full tables are needed for group sizes, dosing and recurrence estimates. The 2004 citation may describe the same study.
Pharmateka. 2005;2(98). · Publication record
Observational study · 2005
[Use of the Gepon immunomodulator for ulcerative colitis treatment].
- Clinical and endoscopic amelioration
- 83.3%Within the treated cohort; no untreated response rate supplied
In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.
Study notes · methods, sources and limitations
Participants or model 36 patients with resistant distal ulcerative colitis
Design 36 patients with resistant distal UC; adjunctive immunomodulation.
- Participants
- 36
Important limitations
- No concurrent comparator is described; the reported response proportion is not an effect versus placebo or standard care. Full methods, reporting completeness and independent replication remain to be appraised.
- The percentage is an uncontrolled response proportion, not a placebo-adjusted remission rate. Long-term relapse and adverse-event rates are not quantified.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 15991847 · Original journal report
About Gepon & ezrin-derived peptides
Names in this research collection
HEP1 · HEP-1 · TEKKRRETVEREKE · HP-V2 · TEKKR · RETVEREKE
Identity / background source ↗
Research background
An ezrin-related peptide family with a patent identity trail, an uncontrolled human ulcerative-colitis report and preclinical experiments. Related fragments are separate research objects.
- Compound class
- Peptide research family
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
36 patients with resistant distal ulcerative colitis
Study methods
Study records describe the tested models, comparators and reported outcomes.
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Comparison in people · 2004
Gepon and Immunomax in 126 people with acute surgical wound infections
In wounds healing by secondary intention, healing averaged 18.4 vs 20.5 days with the combination and comparison care, respectively.
Complete wound healing by secondary intention · 18.4 ± 1.3 vs 20.5 ± 1.4 days · p<0.05 as reported
Study notes and original source
Gepon and Immunomax in 126 people with acute surgical wound infections
A. P. Chadaev, A. M. Nurpisov, A. V. Pichugin, R. I. Ataullakhanov · Russian Medical Journal. 2004;(24). Also published in Pharmateca.
In wounds healing by secondary intention, healing averaged 18.4 vs 20.5 days with the combination and comparison care, respectively.
Results and tables
Reported findings and study design
Single-center comparative series. Both groups received surgery and wound care. Outcomes included wound planimetry and time to clearing and healing.
Population or model 126 surgical patients with acute purulent soft-tissue infection. Combination group: 65. Standard-care comparison: 61.
Dose, route and schedule
Immunomax 200 units intramuscularly on alternate days for three injections, then topical 0.004% Gepon dressings as the wound entered the second phase. Comparison care included 10% methyluracil in that phase.
Protocol source ↗ · Original Russian Medical Journal article and matching Pharmateca report.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Complete wound healing by secondary intention | 18.4 ± 1.3 vs 20.5 ± 1.4 days | p<0.05 as reported |
| Clearance of purulent necrotic material | 9.9 ± 1.2 vs 12.5 ± 1.5 days | |
| Day-three wound area as percentage of baseline | 93.5 ± 2.4% vs 96.5 ± 2.1% | The paper reports significance against baseline. |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 126 surgical patients with acute purulent soft-tissue infection. Combination group: 65. Standard-care comparison: 61.
- Source reviewed
- Original Russian Medical Journal article and matching Pharmateca report.
Study limitations
- Concurrent treatments differed. The effect of Gepon alone cannot be estimated from this comparison. The healing figure concerns the secondary-intention subset.
- The two journals report the same 126 patients and regimen.
Reviewed 2026-11-15.
Comparison in people · 2005
Gepon versus valacyclovir in recurrent genital herpes
The authors reported faster lesion healing and less severe recurrence symptoms with Gepon. They reported no extension of remission with Gepon.
Study notes and original source
Gepon versus valacyclovir in recurrent genital herpes
L. A. Marchenko, I. A. Lushkova, A. V. Shurshalina · Pharmateka. 2005;2(98).
The authors reported faster lesion healing and less severe recurrence symptoms with Gepon. They reported no extension of remission with Gepon.
Results and tables
Reported findings and study design
Clinical treatment comparison during recurrence, based on the original publisher abstract.
Population or model 42 women with severe recurrent genital herpes. Arm sizes were not stated in the accessible original abstract.
Protocol information
Oral and topical Gepon during a recurrence versus valacyclovir. Dose, schedule and comparator allocation are unavailable in the publisher abstract.
Protocol source ↗ · Original publisher abstract. A 2004 citation lists matching authors and topic.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Epithelialization and lesion healing | Reported faster with Gepon | Numerical effect unavailable in the abstract. |
| Length of remission | No extension with Gepon | The abstract describes an extension with valacyclovir. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 42 women with severe recurrent genital herpes. Arm sizes were not stated in the accessible original abstract.
- Source reviewed
- Original publisher abstract. A 2004 citation lists matching authors and topic.
Study limitations
- The full tables are needed for group sizes, dosing and recurrence estimates. The 2004 citation may describe the same study.
Reviewed 2026-11-14.
Observational study · 2005
[Use of the Gepon immunomodulator for ulcerative colitis treatment].
In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.
Study notes and original source
[Use of the Gepon immunomodulator for ulcerative colitis treatment].
· Original journal report
Malakhova NS, Pichugin AV, Khalif IL, Ataullakhanov RI · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 15991847
In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.
Results and tables
Reported findings and study design
In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.
36 patients with resistant distal UC; adjunctive immunomodulation.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical and endoscopic amelioration | 83.3% | Within the treated cohort; no untreated response rate supplied |
| Participants | 36 |
The percentage is an uncontrolled response proportion, not a placebo-adjusted remission rate. Long-term relapse and adverse-event rates are not quantified.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 36 patients with resistant distal ulcerative colitis
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- No concurrent comparator is described; the reported response proportion is not an effect versus placebo or standard care.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-11-01.
Animal research · 2020
Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes.
Gepon reduced experimental colitis manifestations, inflammatory-cell infiltration and selected inflammatory gene signals.
Study notes and original source
Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes.
· Original journal report
Chulkina MM, Pichugin AV, Ataullakhanov RI · Peptides · PMID 32621844
Gepon reduced experimental colitis manifestations, inflammatory-cell infiltration and selected inflammatory gene signals.
- Population / setting
- Mice with dextran-sodium-sulphate-induced colitis
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- A chemically induced mouse model does not establish benefit or safety in human ulcerative colitis.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-10-05.
Lab research · 2017
Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts.
The defined TEKKRRETVEREKE peptide promoted differentiation-related changes through ERK1/2 signaling without SMAD activation.
Study notes and original source
Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts.
· Original journal report
Chulkina M, Negmadjanov U, Lebedeva E, Pichugin A, Mazurov D, Ataullakhanov R, Holmuhamedov E · European journal of pharmacology · PMID 28668507
The defined TEKKRRETVEREKE peptide promoted differentiation-related changes through ERK1/2 signaling without SMAD activation.
- Population / setting
- NIH/3T3 mouse fibroblasts, including CD44-knockout cells
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- Cell signaling does not quantify wound healing in patients.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-10-05.
Experiment described in a patent · 2017
Ezrin-derived peptides and pharmaceutical compositions — US9682140B2
The granted claim class defines modified ezrin-derived peptides, including GEKKRRETVEREGG. A dependent composition also includes the parent Gepon sequence TEKKRRETVEREKE. Modified peptides and mixtures must not inherit Gepon clinical outcomes.
Phospho-ERK1 · 0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control · Normalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02 · 1 hour · p<0.01
Study notes and original source
Ezrin-derived peptides and pharmaceutical compositions — US9682140B2
· Primary source linked above
The granted claim class defines modified ezrin-derived peptides, including GEKKRRETVEREGG. A dependent composition also includes the parent Gepon sequence TEKKRRETVEREKE. Modified peptides and mixtures must not inherit Gepon clinical outcomes.
Results and tables
Reported patent results
Reported findings
The modified peptide increased MAPK/ERK phosphorylation in cell cultures.
Fibroblast signaling experiments with modified ezrin-derived HP-V2; a different sequence from parent Gepon.
Population or model Ezrin-related patent chemistry and experimental examples
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Phospho-ERK1 | 0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control | Normalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02 · 1 hour · p<0.01 |
| Phospho-ERK2 | 1.30 ± 0.05 versus 0.40 ± 0.01 negative control | Positive TGF-β1 control 1.90 ± 0.10 · 1 hour · p<0.01 |
A fibroblast pathway response does not prove tissue repair or clinical efficacy. Values belong to HP-V2, not automatically Gepon, related fragments or every mixture.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Ezrin-related patent chemistry and experimental examples
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Modified sequences and mixtures must not inherit Gepon outcomes.
- Clinical evidence appraisal remains pending.
Reviewed 2026-11-06.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗